RAPONI, SARA
 Distribuzione geografica
Continente #
NA - Nord America 1.199
EU - Europa 443
AS - Asia 297
AF - Africa 15
SA - Sud America 11
OC - Oceania 4
Totale 1.969
Nazione #
US - Stati Uniti d'America 1.191
SG - Singapore 165
IT - Italia 149
SE - Svezia 145
CN - Cina 67
IN - India 57
FI - Finlandia 46
DE - Germania 44
UA - Ucraina 16
TG - Togo 12
GB - Regno Unito 11
AR - Argentina 9
CA - Canada 8
RO - Romania 8
BG - Bulgaria 7
ID - Indonesia 6
IE - Irlanda 5
AU - Australia 4
NL - Olanda 4
BE - Belgio 3
ZA - Sudafrica 3
BD - Bangladesh 1
CH - Svizzera 1
CL - Cile 1
CO - Colombia 1
FR - Francia 1
GR - Grecia 1
HU - Ungheria 1
LT - Lituania 1
PH - Filippine 1
Totale 1.969
Città #
Fairfield 206
Singapore 136
Seattle 82
Chandler 80
Ashburn 75
Woodbridge 63
Wilmington 60
Houston 55
Cambridge 53
Rome 52
Ann Arbor 47
Princeton 39
Santa Clara 38
Stockholm 33
Beijing 32
Bremen 28
Plano 26
Boston 22
Helsinki 21
Millbury 19
Andover 15
Lawrence 14
San Paolo di Civitate 14
San Diego 13
Dearborn 12
Lomé 12
Federal 8
Sofia 7
Cagliari 6
Nuoro 6
Toronto 6
Dublin 5
Jacksonville 5
Jakarta 5
New York 5
Norwalk 5
Turin 5
Des Moines 4
San Mateo 4
Southend 4
Walsall 4
Brussels 3
Bühl 3
Falls Church 3
Florence 3
Gossolengo 3
Hefei 3
Indiana 3
Mannheim 3
Sacramento 3
Seveso 3
Solbiate Arno 3
Sydney 3
Accadia 2
Amsterdam 2
Bologna 2
Cape Town 2
Falkenstein 2
Guangzhou 2
Lappeenranta 2
London 2
Los Angeles 2
Lucknow 2
Nanjing 2
Naples 2
Pasian di Prato 2
Perugia 2
Pisa 2
Prato 2
Redmond 2
Redwood City 2
Solna 2
Athens 1
Bari 1
Bern 1
Boardman 1
Bogotá 1
Budapest 1
Canyon Country 1
Changsha 1
Chengdu 1
Council Bluffs 1
Delhi 1
Dhaka 1
Fasano 1
Fiuggi 1
Frankfurt am Main 1
Fremont 1
Guwahati 1
Jamshedpur 1
Jinan 1
Kunming 1
Manila 1
Milan 1
Milpitas 1
Monsano 1
Monte 1
Montréal 1
Muizenberg 1
Ningbo 1
Totale 1.428
Nome #
An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia 80
Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. 78
Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. 78
IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells 77
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib 77
Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. 76
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia 75
Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia 74
null 68
TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IMMUNOCHEMOTHERAPY AND IBRUTINIB. 67
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab 66
Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocitic leukemia cells. 66
Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. 65
High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation 63
Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. 61
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal? 60
Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases 60
null 54
Distribution of genetic and molecular prognostic markers in young patients with Chronic Lymphocytic Leukemia (CLL) in different phases of the disease. 54
null 54
null 53
null 51
STUDIO DELL’IMMUNOFENOTIPO NELLE EMOPATIE: IDENTIFICAZIONE DI TARGETS FENOTIPICI COME POTENZIALI BERSAGLI TERAPEUTICI 42
null 42
Chronic lymphocytic leukemia cells from paired lymph node and peripheral blood show a different pattern of copy number aberrations 38
null 36
COMPLEX KARYOTYPE AFTER IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (GIMEMA LLC1114) 32
A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF-V600E mutation: lack of evidence for a common origin 31
null 30
COMPLEX KARYOTYPE IS ASSOCIATED WITH A LESS FAVORABLE OUTCOME AFTER IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (GIMEMA LLC1114). 30
Is the Aberrant Expression of p53 by Immunocytochemistry a Surrogate Marker of TP53 Mutation and/or Deletion in Chronic Lymphocytic Leukemia? 29
TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IBRUTINIB TREATMENT. 28
FLOW CYTOMETRY EVALUATION OF ZAP-70, CD38 AND CD49D ANTIGEN EXPRESSION ON THE NEOPLASTIC CELLS OF PROGRESSIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS 27
null 27
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study 27
Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia 26
IBRUTINIB TREATMENT DOESN’T INDUCE TP53 CLONAL EVOLUTION IN CHRONIC LYMPHOCYTIC LEUKEMIA. 26
Genetic Landscape of Ultra-Stable Chronic Lymphocytic Leukemia Patients 24
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study 23
null 22
Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia 21
Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments 17
Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile 17
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 17
CD45 antigen negativity in T-lineage ALL correlates with PTPRC mutation and sensitivity to a selective JAK inhibitor. 16
Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients 13
Totale 2.098
Categoria #
all - tutte 6.679
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.679


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020248 0 0 0 0 0 44 50 45 47 28 23 11
2020/2021113 14 18 6 8 2 1 1 16 11 21 9 6
2021/2022425 7 19 17 35 41 7 3 50 36 23 99 88
2022/2023383 78 66 42 41 46 42 2 19 30 0 9 8
2023/2024179 18 28 7 17 13 12 1 22 1 13 27 20
2024/2025310 22 143 42 57 27 19 0 0 0 0 0 0
Totale 2.098